Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088541 · ClinicalTrials.gov registry record · Phase 2
Selinexor (KPT-330) in Older Patients With Relapsed AML
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT02088541: Completed Phase 2 study, sponsored by Karyopharm Therapeutics.
NCT02088541 is a Phase 2 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 317 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02088541, a Phase 2 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.
Primary Outcome
Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact.
Interventions
- DRUG Hydroxyurea
- DRUG Selinexor
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 2 |
What the finished NCT02088541 record still lists
NCT02088541 is an interventional study that assigns participants to a tested intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher).
The record links to 0 conditions, and to 3 interventions - of which Hydroxyurea is the first listed.
NCT02088541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02088541 about?
NCT02088541 is a clinical study titled "Selinexor (KPT-330) in Older Patients With Relapsed AML". This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior thera...
What is the current status of trial NCT02088541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2014-03. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02088541?
The interventions under investigation include: Hydroxyurea (DRUG), Selinexor (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT02088541?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02088541's enrollment target sits among peer trials
317 155th of 2000 higher than 1,846 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia